Drug intelligence / Profile preview

BW-1010

Development stage: Phase 1
Lead developer: BlueWillow Biologics
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intranasal

Overview

**BW-1010** is an investigational intranasal anthrax vaccine developed by BlueWillow Biologics and Porton Biopharma. It combines recombinant *Bacillus anthracis* protective antigen with BlueWillow's W805EC/NE01 oil-in-water nanoemulsion adjuvant platform. Intranasal administration is intended to elicit both systemic neutralizing antibody responses and mucosal immunity, including nasal IgA and IgG responses, to protect against anthrax toxin-mediated disease following exposure to *Bacillus anthracis*. BW-1010 completed a Phase 1 study in healthy adults evaluating safety, tolerability, and immunogenicity.

Other names: NanoVax anthrax vaccine

Targets

PA (Influenza polymerase acidic protein)

Beyond the preview

Go deeper on BW-1010.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BW-1010.

Explore the full profile